Reduced NO signaling during pregnancy attenuates outward uterine artery remodeling by altering MMP expression and collagen and elastin deposition

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 4, 2011, Pages

  Hale, Sarah A ^a   Weger, Lindsey ^a   Mandala, Maurizio ^a,b   Osol, George ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Extracellular matrix; Hypertension; Matrix metalloproteinase; Nitric oxide; Pregnancy

Indexed keywords

COLLAGEN; ELASTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTERIAL WALL THICKNESS; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FETUS; FETUS WEIGHT; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; NONHUMAN; PLACENTA WEIGHT; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UTERINE ARTERY; UTERUS CAVITY;

ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; COLLAGEN; ELASTIN; FEMALE; FETUS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PREGNANCY; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UTERINE ARTERY;

EID: 80053292702     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00519.2011     Document Type: Article

References (73)

1. Arribas SM, Hinek A, Gonzalez MC. Elastic fibres and vascular structure in hypertension. Pharmacol Ther 111: 771-791, 2006.
2. Bankowski E, Romanowicz L, Jaworski S. Collagen of umbilical cord arteries and its alterations in EPH-gestosis. J Perinat Med 21: 491-98, 1993.
3. Buhimschi I, Yallampalli C, Chwalisz K, Garfield RE. Pre-eclampsialike conditions produced by nitric oxide inhibition: effects of L-arginine, D-arginine and steroid hormones. Hum Reprod 10: 2723-2730, 1995.
4. Buhimschi IA, Saade GR, Chwalisz K, Garfield RE. The nitric oxide pathway in pre-eclampsia: pathophysiological implications. Hum Reprod Update 4: 25-42, 1998.
5. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253: 269-285, 2003.
6. Chen HH, Wang DL. Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells. Mol Pharmacol 65: 1130-1140, 2004.
7. Chen LL, Zhu TB, Yin H, Huang J, Wang LS, Cao KJ, Yang ZJ. Inhibition of MAPK signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through reduction of inflammation. Mol Biol Rep 37: 3067-3072, 2009.
8. Cipolla MJ, Bishop N, Vinke RS, Godfrey JA. PPAR activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats. Stroke 41: 1266-1270, 2010.
9. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF. Matrix metalloproteinase-2, -9, and tissue inhibitor of metal- loproteinase-1 in patients with hypertension. Endothelium 13: 227-231, 2006.
10. Edwards DL, Arora CP, Bui DT, Castro LC. Long-term nitric oxide blockade in the pregnant rat: effects on blood pressure and plasma levels of endothelin-1. Am J Obstet Gynecol 175: 484-488, 1996.
11. English JL, Kassiri Z, Koskivirta I, Atkinson SJ, Di Grappa M, Soloway PD, Nagase H, Vuorio E, Murphy G, Khokha R. Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem 281: 10337-10346, 2006.
12. Filippov S, Koenig GC, Chun TH, Hotary KB, Ota I, Bugge TH, Roberts JD, Fay WP, Birkedal-Hansen H, Holmbeck K, Sabeh F, Allen ED, Weiss SJ. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J Exp Med 202: 663-671, 2005.
13. Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 16: 150-159, 1996.
14. Galewska Z, Bankowski E, Romanowicz L, Jaworski S. Pre-eclampsi (EPH-gestosis)-induced decrease of MMP-s content in the umbilical cord artery. Clinica Chimica Acta 335: 109-115, 2003.
15. Galewska Z, Romanowicz L, Jaworski S, Bankowski E. Matrix metalloproteinases, MMP-7 and MMP-26, in plasma and serum of control and preeclamptic umbilical cord blood. Eur J Obstet Gynecol Reprod Biol 150: 152-156, 2010.
16. Garanich JS, Pahakis M, Tarbell JM. Shear stress inhibits smooth muscle cell migration via nitric oxide-mediated downregulation of matrix metalloproteinase-2 activity. Am J Physiol Heart Circ Physiol 288: H2244-H2252, 2005.
17. Genis L, Gonzalo P, Tutor AS, Galvez BG, Martinez-Ruiz A, Zaragoza C, Lamas S, Tryggvason K, Apte SS, Arroyo AG. Functional interplay between endothelial nitric oxide synthase and membrane type 1 matrix metalloproteinase in migrating endothelial cells. Blood 110: 2916-2923, 2007.
18. George E, Granger J. Mechanisms and potential therapies for preeclampsia. Current Hypertension Reports: 1-7, 2011.
19. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 294: H541-H550, 2008.
20. Grandas OH, Mountain DH, Kirkpatrick SS, Cassada DC, Stevens SL, Freeman MB, Goldman MH. Regulation of vascular smooth muscle cell expression and function of matrix metalloproteinases is mediated by estrogen and progesterone exposure. J Vasc Surg 49: 185-191, 2009.
21. Haas TL, Doyle JL, Distasi MR, Norton LE, Sheridan KM, Unthank JL. Involvement of MMPs in the outward remodeling of collateral mesenteric arteries. Am J Physiol Heart Circ Physiol 293: H2429-H2437, 2007.
22. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 278: 28-45.
23. Helmbrecht GD, Farhat MY, Lochbaum L, Brown HE, Yadgarova KT, Eglinton GS, Ramwell PW. L-arginine reverses the adverse pregnancy changes induced by nitric oxide synthase inhibition in the rat. Am J Obstet Gynecol 175: 800-805, 1996.
24. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal- Hansen H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99: 81-92, 1999.
25. Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension 33: 569-574, 1999.
26. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 36: 312-318, 2000.
27. Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S. Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 272: 22389-22392, 1997.
28. Itoh Y. MT1-MMP: a key regulator of cell migration in tissue. IUBMB Life 58: 589-596, 2006.
29. Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 206: 1-8, 2006.
30. Jeyabalan A, Shroff SG, Novak J, Conrad KP. The vascular actions of relaxin. Adv Exp Med Biol 612: 65-87, 2007.
31. Kang H, Bayless KJ, Kaunas R. Fluid shear stress modulates endothelial cell invasion into three-dimensional collagen matrices. Am J Physiol Heart Circ Physiol 295: H2087-H2097, 2008.
32. Kelly BA, Bond BC, Poston L. Gestational profile of matrix metalloproteinases in rat uterine artery. Mol Hum Reprod 9: 351-358, 2003.
33. Kuno Y, Iyoda M, Shibata T, Hirai Y, Akizawa T. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. Br J Pharmacol 162: 1389-1400, 2011.
34. Lafleur MA, Tester AM, Thompson EW. Selective involvement of TIMP-2 in the s activational cleavage of pro-MMP-2: refinement of the pro-MMP-2 activation mechanism. FEBS Lett 553: 457-463, 2003.
35. Lam KK, Cheng PY, Hsiao G, Chen SY, Shen HH, Yen MH, Lee YM. Estrogen deficiency-induced alterations of vascular MMP-2, MT1-MMP, and TIMP-2 in ovariectomized rats. Am J Hypertens 22: 27-34, 2008.
36. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98: 535-540, 1998.
37. Leona CYP, Ekaterina N, Panagiotis A, Panagiotis L, Kypros HN. First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome. Prenatal Diagnosis 29: 553-559, 2009.
38. Lounsbury KM, Beddow AL, Macara IG. A family of proteins that stabilize the Ran/TC4 GTPase in its GTP-bound conformation. J Biol Chem 269: 11285-11290, 1994.
39. Lubarsky SL, Ahokas RA, Friedman SA, Sibai BM. The effect of chronic nitric oxide synthesis inhibition on blood pressure and angiotensin II responsiveness in the pregnant rat. Am J Obstet Gynecol 176: 1069-1076, 1997.
40. Magness RR, Shaw CE, Phernetton TM, Zheng J, Bird IM. Endothelial vasodilator production by uterine and systemic arteries. II. Pregnancy effects on NO synthase expression. Am J Physiol Heart Circ Physiol 272: H1730-H1740, 1997.
41. Magness RR, Sullivan JA, Li Y, Phernetton TM, Bird IM. Endothelial vasodilator production by uterine and systemic arteries. VI. Ovarian and pregnancy effects on eNOS and NOx. Am J Physiol Heart Circ Physiol 280: H1692-H1698, 2001.
42. Matsubara K, Matsubara Y, Hyodo S, Katayama T, Ito M. Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. J Obstet Gynaecol Res 36: 239-247, 2010.
43. Meehan DT, Delimont D, Cheung L, Zallocchi M, Sansom SC, Holzclaw JD, Rao V, Cosgrove D. Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease. Kidney Int 76: 968-976, 2009.
44. Miller SL, Jenkin G, Walker DW. Effect of nitric oxide synthase inhibition on the uterine vasculature of the late-pregnant ewe. Am J Obstet Gynecol 180: 1138-1145, 1999.
45. Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno G, Franchi M, Guidi G. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal 23: 88-92, 2009.
46. Nelson SH, Steinsland OS, Wang Y, Yallampalli C, Dong YL, Sanchez JM. Increased Nitric Oxide Synthase Activity and Expression in the Human Uterine Artery During Pregnancy. Circ Res 87: 406-411, 2000.
47. Novaro V, Colman-Lerner A, Ortega FV, Jawerbaum A, Paz D, Lo Nostro F, Pustovrh C, Gimeno MF, Gonzalez E. Regulation of metalloproteinases by nitric oxide in human trophoblast cells in culture. Reprod Fertil Dev 13: 411-420, 2001.
48. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 272: 2446-2451, 1997.
49. Ong SS, Baker PN, Mayhew TM, Dunn WR. Remodeling of myometrial radial arteries in preeclampsia. Am J Obstet Gynecol 192: 572-579, 2005.
50. Osol G, Barron C, Gokina N, Mandala M. Inhibition of nitric oxide synthases abrogates pregnancy-induced uterine vascular expansive remodeling. J Vasc Res 46: 478-486, 2009.
51. Osol G, Mandala M. Maternal uterine vascular remodeling during pregnancy. Physiology (Bethesda) 24: 58-71, 2009.
52. Palei ACT, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 41: 875-880, 2008.
53. Palumbo R, Gaetano C, Melillo G, Toschi E, Remuzzi A, Capogrossi MC. Shear stress downregulation of platelet-derived growth factor receptor-β and matrix metalloprotease-2 is associated with inhibition of smooth muscle cell invasion and migration. Circulation 102: 225-230, 2000.
54. Pustovrh MC, Jawerbaum A, White V, Capobianco E, Higa R, Martinez N, Lopez-Costa JJ, Gonzalez E. The role of nitric oxide on matrix metalloproteinase 2 (MMP2) and MMP9 in placenta and fetus from diabetic rats. Reproduction 134: 605-613, 2007.
55. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75: 346-359, 2008.
56. Robinson EK, Seaworth CM, Suliburk JW, Adams SD, Kao LS, Mercer DW. Effect of nos inhibition on rat gastric matrix metalloproteinase production during endotoxemia. Shock 25: 507-514, 2006.
57. Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem 278: 9472-9480, 2003.
58. Shelton L, Rada JS. Effects of cyclic mechanical stretch on extracellular matrix synthesis by human scleral fibroblasts. Exp Eye Res 84: 314-322, 2007.
59. Spanikova A, Simoncikova P, Ravingerova T, Pechanova O, Barancik M. The effect of chronic nitric oxide synthases inhibition on regulatory proteins in rat hearts. Mol Cell Biochem 312: 113-120, 2008.
60. Standley CA, Batia L, Yueh G. Magnesium sulfate effectively reduces blood pressure in an animal model of preeclampsia. J Matern Fetal Neonatal Med 19: 171-176, 2006.
61. Thaete LG, Kushner DM, Dewey ER, Neerhof MG. Endothelin and the regulation of uteroplacental perfusion in nitric oxide synthase inhibitioninduced fetal growth restriction. Placenta 26: 242-250, 2005.
62. Toth M, Bernardo MM, Gervasi DC, Soloway PD, Wang Z, Bigg HF, Overall CM, DeClerck YA, Tschesche H, Cher ML, Brown S, Mobashery S, Fridman R. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMPdependent activation of pro-MMP-2. J Biol Chem 275: 41415-41423, 2000.
63. Tronc F, Wassef M, Esposito B, Henrion D, Glagov S, Tedgui A. Role of NO in flow-induced remodeling of the rabbit common carotid artery. Arterioscler Thromb Vasc Biol 16: 1256-1262, 1996.
64. van der Heijden OW, Essers YP, Fazzi G, Peeters LL, De Mey JG, van Eys GJ. Uterine artery remodeling and reproductive performance are impaired in endothelial nitric oxide synthase-deficient mice. Biol Reprod 72: 1161-1168, 2005.
65. Vanderlelie JJ, Perkins AV. Chronic nitric oxide synthase inhibition in pregnant rats does not result in placental oxidative stress. Hypertens Pregnancy 25: 103-114, 2006.
66. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003.
67. Wang H, Olszewski B, Rosebury W, Wang D, Robertson A, Keiser JA. Impaired angiogenesis in SHR is associated with decreased KDR and MT1-MMP expression. Biochem Biophys Res Commun 315: 363-368, 2004.
68. Wang Z, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 275: 26411-26415, 2000.
69. Yamaguchi S, Yamaguchi M, Yatsuyanagi E, Yun SS, Nakajima N, Madri JA, Sumpio BE. Cyclic strain stimulates early growth response gene product 1-mediated expression of membrane type 1 matrix metalloproteinase in endothelium. Lab Invest 82: 949-956, 2002.
70. Yang YL, Liu DD, Hsieh NK, Chen HI. Endothelin and gelatinases in renal changes following blockade of nitric oxide synthase in hypertensive rats. Chin J Physiol 51: 186-195, 2008.
71. Yu LB, Dong XS, Sun WZ, Zhao DL, Yang Y. Effect of a nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester on invasion of human colorectal cancer cell line SL-174T. World J Gastroenterol 11: 6385-6388, 2005.
72. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C, Vasiliadou K, Toutouza M, Toutouzas P. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 17: 119-124, 2003.
73. Zhang X, Wang HM, Lin HY, Liu GY, Li QL, Zhu C. Regulation of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) during mouse peri-implantation: role of nitric oxide. Placenta 25: 243-252, 2004.